Automated Blood Analysis Funding Boost: Scopio Labs Secures Additional $10 Million for Blood Morphology Automation Technology
Scopio Labs, a pioneering company in the field of digital hematology, has announced the launch of its new AI-based CBM analyzer. This groundbreaking technology is set to transform the hematology market and traditional blood morphology diagnostic processes by introducing a fully autonomous, AI-powered system [1][3].
The CBM analyzer automates the traditionally manual blood morphology diagnostic process, potentially eliminating the need for routine human reviews. By examining ten times more cells than current methods, it provides a more comprehensive analysis of blood smears, potentially improving diagnostic sensitivity and specificity in hematology [1][2].
The automation and scalability offered by the CBM analyzer could significantly reduce variability and human workload while increasing throughput and consistency in labs [1][3]. This shift towards AI-driven analysis is expected to enhance lab efficiency, reproducibility, and patient care outcomes while aligning with broader trends in digital hematopathology [1][3][4].
Viola Growth, a leading investor in the life sciences sector, has shown faith in Scopio Labs' innovation by investing an additional $10 million, raising Scopio's Series D funding to $52 million [1][5]. Viola Growth views the CBM analyzer as a major leap forward for hematology labs, believing it offers the depth, speed, and scalability that the critical morphology review step urgently needs.
Scopio Labs' CBM utilizes the company's Full-Field technology, which combines advanced imaging and AI to automate and standardize Peripheral Blood Smears (PBS) reviews. The company aims to be the first to automate the entire hematology process from Complete Blood Count (CBC) to final result [2].
The CBM analyzer holds CE-marked and FDA-cleared digital imaging applications, demonstrating its regulatory progress and market readiness. While the CBM analyzer itself remains under development and not yet available for in vitro diagnostic use, its upcoming presentation at the ADLM 2025 conference signals forthcoming market introduction and adoption opportunities [1][3].
Scopio's CEO, Itai Hayut, believes the CBM will transform the hematology market, stating, "The CBM analyzer represents a significant advancement in hematology lab technology." As the CBM analyzer continues to develop, it is poised to reshape conventional hematology workflows, potentially paving the way for the development of accurate and consistent morphology-based biomarkers and diagnostic panels beyond automation [1][3][4].
In conclusion, the CBM analyzer is expected to revolutionize the hematology market by introducing a fully autonomous, AI-powered system that promises to enhance lab efficiency, reproducibility, and patient care outcomes while aligning with broader trends in digital hematopathology.
[1] Scopio Labs. (n.d.). Scopio Labs Launches New AI-Based Complete Blood Morphology (CBM) Analyzer. Retrieved from https://www.scopiolabs.com/press-releases/scopio-labs-launches-new-ai-based-complete-blood-morphology-cbm-analyzer
[2] Viola Growth. (n.d.). Viola Growth Leads Scopio Labs' $52M Series D Round. Retrieved from https://www.violagrowth.com/news/viola-growth-leads-scopio-labs-52m-series-d-round
[3] Scopio Labs. (n.d.). Scopio Labs' CBM Analyzer to be Showcased at ADLM 2025 Annual Conference. Retrieved from https://www.scopiolabs.com/press-releases/scopio-labs-cbm-analyzer-to-be-showcased-at-adlm-2025-annual-conference
[4] Scopio Labs. (n.d.). Scopio Labs' CBM Analyzer to Reshape Hematology Market. Retrieved from https://www.scopiolabs.com/press-releases/scopio-labs-cbm-analyzer-to-reshape-hematology-market
[5] Viola Growth. (n.d.). Viola Growth Joins Scopio Labs on Journey to Reshape Future of Hematology Diagnostics. Retrieved from https://www.violagrowth.com/news/viola-growth-joins-scopio-labs-on-journey-to-reshape-future-of-hematology-diagnostics
The CBM analyzer, developed by Scopio Labs, promotes advancements in the field of hematology and health-and-wellness by leveraging technology to automate and standardize medical-condition diagnostic processes. The AI-driven system is anticipated to improve lab efficiency, reproducibility, and patient care outcomes in the medical sector, aligning with trends in digital hematopathology.
Viola Growth's investment in Scopio Labs signifies the firm's confidence in the potential of the CBM analyzer to revolutionize hematology labs and address the critical need for depth, speed, and scalability in traditional diagnostic methods, ultimately contributing to science and technology advancement.
